Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion Inhibitor

Cervia, Joseph S.; Smith, Miriam A.
October 2003
Clinical Infectious Diseases;10/15/2003, Vol. 37 Issue 8, p1102
Academic Journal
Describes the development of highly active antiretroviral therapy in reducing the progression of AIDS in HIV-infected patients in the U.S. Improvement of the life expectancy of patients; Conformational changes in the HIV envelope glycoprotein 41; Sensitivity of viral envelope to synthetic peptide enfuvirtide.


Related Articles

  • When to Start Antiretroviral Therapy in Resource-Limited Settings. Rochelle P. Walensky; Lindsey L. Wolf; Robin Wood; Mariam O. Fofana; Kenneth A. Freedberg; Neil A. Martinson; A. David Paltiel; Xavier Anglaret; Milton C. Weinstein; Elena Losina // Annals of Internal Medicine;8/4/2009, Vol. 151 Issue 3, p157 

    Background: The results of international clinical trials that are assessing when to initiate antiretroviral therapy (ART) will not be available for several years. Objective: To inform HIV treatment decisions about the optimal CD4 threshold at which to initiate ART in South Africa while awaiting...

  • LATE REPORTING AMONG NEWLY REGISTERED PATIENTS FOR ANTI RETROVIRAL THERAPY IN A CENTRAL DISTRICT UJJAIN, INDIA. Khandelwal, Vidit; Sabde, Yogesh D.; Pradhan, Riddhi; Sathsh, Mehta Chandra // National Journal of Community Medicine;Oct-Dec2013, Vol. 4 Issue 4, p624 

    Introduction: Current trends in HIV/AIDS epidemic demand quality and sustainable programs to provide universal access to antiretroviral therapy (ART). The inherent disparities in population subgroups result in changing profiles of ART beneficiaries which are needed to account for with reference...

  • Free antiretroviral treatment effective in Malawi.  // Infectious Disease News;Jun2008, Vol. 21 Issue 6, p39 

    The article reports on the results of a study on the efficiency of antiretroviral therapy in Malawi. It revealed that mortality rates of patients with HIV and AIDS have been reduced following the introduction of free antiretroviral therapy. According to researchers, the mortality rate was 9.8...

  • Role of Uncontrolled HIV RNA Level and Immunodeficiency in the Occurrence of Malignancy in HIV-Infected Patients during the Combination Antiretroviral Therapy Era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Bruyand, Mathias; Thie'baut, Rodolphe; Lawson-Ayayi, Sylvie; Joly, Pierre; Sasco, Annie Jeanne; Mercie', Patrick; Pellegrin, Jean Luc; Neau, Didier; Dabis, François; Morlat, Philippe; Chêne, Geneviève; Bonnet, Fabrice // Clinical Infectious Diseases;10/1/2009, Vol. 49 Issue 7, p1109 

    Background. Human immunodeficiency virus (HIV)-infected patients are at higher risk of malignancies. In addition to traditional determinants, a specific deleterious effect of HIV and immunodeficiency is speculated. We aimed at studying the association between immunological and virological...

  • Cancer Burden Shifts for People With HIV/AIDS.  // JNCI: Journal of the National Cancer Institute;May2011, Vol. 103 Issue 9, pNP 

    The article discusses the findings of research about the incidence and types of cancer among people with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) in the U.S. According to researchers from the National Cancer Institute (NCI) and the Centers for Disease Control...

  • Optimizing Predictive Mining Techniques in HIV-Related Opportunistic Infections: Case for Botswana. Buthu'gwashe; Zhiyong Li; Kirui, Clement // International Journal of Computer Applications;Aug2013, Vol. 76 Issue 1-16, p1 

    Botswana was one of the first countries to establish a national Antiretroviral therapy (ART) programme in Africa. "Masa," a native word depicting "a new dawn," is the programme name. The AIDS epidemic has led to the emergence of several disease entities which in the pre-AIDS era seemed...

  • Comparing antiretroviral treatment outcomes between a prospective community-based and hospital-based cohort of HIV patients in rural Uganda. Kipp, Walter; Konde-Lule, Joseph; Rubaale, Tom; Okech-Ojony, Joa; Alibhai, Arif; Saunders, Duncan L. // BMC International Health & Human Rights;2011 Supplement 2, Vol. 11 Issue Suppl 2, p1 

    Background: Improved availability of antiretroviral therapy in sub-Saharan Africa is intended to benefit all eligible HIV-infected patients; however in reality antiretroviral services are mainly offered in urban hospitals. Poor rural patients have difficulty accessing the drugs, making the...

  • Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe. Walker, A. Sarah; Prendergast, Andrew J.; Mugyenyi, Peter; Munderi, Paula; Hakim, James; Kekitiinwa, Addy; Katabira, Elly; Gilks, Charles F.; Kityo, Cissy; Nahirya-Ntege, Patricia; Nathoo, Kusum; Gibb, Diana M. // Clinical Infectious Diseases;Dec2012, Vol. 55 Issue 12, p1707 

    In low-income countries, children ≥4 years and adults with low CD4 count have equally high mortality risk in the 3 months after initiation of antiretroviral therapy, similar to that of untreated individuals. Bacterial infections play a major role; targeted interventions could have...

  • Quantifying and Predicting the Effect of Exogenous Interleukin-7 on CD4+T Cells in HIV-1 Infection. Thiébaut, Rodolphe; Drylewicz, Julia; Prague, Mélanie; Lacabaratz, Christine; Beq, Stéphanie; Jarne, Ana; Croughs, Thérèse; Sekaly, Rafick-Pierre; Lederman, Michael M.; Sereti, Irini; Commenges, Daniel; Lévy, Yves // PLoS Computational Biology;May2014, Vol. 10 Issue 5, p1 

    Exogenous Interleukin-7 (IL-7), in supplement to antiretroviral therapy, leads to a substantial increase of all CD4+ T cell subsets in HIV-1 infected patients. However, the quantitative contribution of the several potential mechanisms of action of IL-7 is unknown. We have performed a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics